Aureus Asset Management LLC raised its position in CME Group Inc (NASDAQ:CME) by 8.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 91,412 shares of the financial services provider’s stock after acquiring an additional 7,160 shares during the quarter. CME Group makes up about 2.0% of Aureus Asset Management LLC’s investment portfolio, making the stock its 26th largest holding. Aureus Asset Management LLC’s holdings in CME Group were worth $12,403,000 at the end of the most recent reporting period.
Other hedge funds have also recently made changes to their positions in the company. Fiduciary Trust Co. acquired a new stake in shares of CME Group during the 2nd quarter worth about $105,000. Quadrant Capital Group LLC lifted its stake in shares of CME Group by 13.6% during the 2nd quarter. Quadrant Capital Group LLC now owns 944 shares of the financial services provider’s stock worth $111,000 after buying an additional 113 shares during the last quarter. San Francisco Sentry Investment Group CA acquired a new stake in shares of CME Group during the 2nd quarter worth about $129,000. People s United Financial Inc. lifted its stake in shares of CME Group by 11.5% during the 2nd quarter. People s United Financial Inc. now owns 1,063 shares of the financial services provider’s stock worth $133,000 after buying an additional 110 shares during the last quarter. Finally, Parallel Advisors LLC lifted its stake in shares of CME Group by 12.2% during the 2nd quarter. Parallel Advisors LLC now owns 1,216 shares of the financial services provider’s stock worth $149,000 after buying an additional 132 shares during the last quarter. Hedge funds and other institutional investors own 83.17% of the company’s stock.
CME Group Inc (NASDAQ:CME) opened at $153.41 on Tuesday. CME Group Inc has a 1 year low of $113.27 and a 1 year high of $154.03. The company has a market cap of $51,960.00, a PE ratio of 31.55, a P/E/G ratio of 3.10 and a beta of 0.73. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.05 and a current ratio of 1.05.
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 27th. Investors of record on Friday, December 8th will be given a dividend of $0.66 per share. This represents a $2.64 dividend on an annualized basis and a yield of 1.72%. The ex-dividend date of this dividend is Thursday, December 7th. CME Group’s dividend payout ratio is 59.86%.
In other CME Group news, Director Jeffrey M. Bernacchi sold 1,501 shares of the firm’s stock in a transaction dated Thursday, November 30th. The shares were sold at an average price of $149.75, for a total value of $224,774.75. Following the transaction, the director now directly owns 60,194 shares of the company’s stock, valued at approximately $9,014,051.50. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Kimberly S. Taylor sold 8,125 shares of the firm’s stock in a transaction dated Thursday, November 30th. The shares were sold at an average price of $150.00, for a total transaction of $1,218,750.00. Following the completion of the transaction, the insider now directly owns 120,590 shares in the company, valued at $18,088,500. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 35,635 shares of company stock worth $5,108,354. 0.57% of the stock is owned by insiders.
A number of research firms have recently issued reports on CME. BidaskClub upgraded shares of CME Group from a “hold” rating to a “buy” rating in a research note on Friday, August 18th. Citigroup raised their target price on shares of CME Group from $138.00 to $155.00 and gave the stock a “buy” rating in a research note on Thursday, October 19th. Keefe, Bruyette & Woods restated a “hold” rating and set a $127.00 target price on shares of CME Group in a research note on Friday, August 18th. UBS restated a “buy” rating and set a $135.00 target price (up previously from $134.00) on shares of CME Group in a research note on Wednesday, September 6th. Finally, Barclays raised their target price on shares of CME Group from $139.00 to $149.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 10th. One analyst has rated the stock with a sell rating, four have given a hold rating and seven have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $141.75.
ILLEGAL ACTIVITY NOTICE: This report was posted by Community Financial News and is the property of of Community Financial News. If you are reading this report on another publication, it was copied illegally and republished in violation of US and international trademark and copyright law. The original version of this report can be viewed at https://www.com-unik.info/2017/12/05/cme-group-inc-cme-holdings-increased-by-aureus-asset-management-llc.html.
CME Group Company Profile
CME Group Inc, through its exchanges, provides products across all asset classes, including futures and options based on interest rates, equity indexes, foreign exchange, energy, agricultural products and metals. The Company’s segment primarily consists of the Chicago Mercantile Exchange Inc (CME), Board of Trade of the City of Chicago, Inc (CBOT), New York Mercantile Exchange, Inc (NYMEX) and Commodity Exchange, Inc (COMEX) exchanges.
Want to see what other hedge funds are holding CME? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CME Group Inc (NASDAQ:CME).
What are top analysts saying about CME Group Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for CME Group Inc and related companies.